Sofinnova’s Maha Katabi on recent M&A and IPO success and how deal flow has ‘never been any better’
16 Feb 2024
IPOExecutive ChangeAcquisition
Maha Katabi has had a great three months. The Sofinnova general partner has been in the boardroom of two recent M&A exits: radiopharmaceuticals maker RayzeBio, sold to Bristol Myers Squibb, and asthma startup Aiolos Bio, to GSK.
Katabi, who joined Sofinnova in 2019 after roles at Oxalis Capital and Sectoral Asset Management, is one of the leaders of the third-most active investor in private biotech financings last year, per a January report from investment bank William Blair. Sofinnova also recently led a $170 million Series D for BioAge to run mid-stage obesity trials.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.